Off-Label Use of Bevacizumab for Wet Age-Related Macular Degeneration in Europe

Graefe's Archive for Clinical and Experimental Ophthalmology - Germany
doi 10.1007/s00417-019-04569-8
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Burden of Wet Age-Related Macular Degeneration in China

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Focal Macular Electroretinograms After Intravitreal Injections of Bevacizumab for Age-Related Macular Degeneration

Investigative Ophthalmology and Visual Science
Molecular NeuroscienceOphthalmologySensory SystemsCellular
2012English

Effect of Intravitreal Bevacizumab on Visual Acuity and Optical Coherence Tomography (Oct) Changes in Wet Age-Related Macular Degeneration

Journal of Evidence Based Medicine and Healthcare
2019English

Intravitreal Bevacizumab vs Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration

Archives of Ophthalmology
2007English

Evaluation of Cardiovascular Biomarkers in Patients With Age-Related Wet Macular Degeneration

Clinical Ophthalmology
Ophthalmology
2014English

PPAR-αLigands as Potential Therapeutic Agents for Wet Age-Related Macular Degeneration

PPAR Research
Drug DiscoveryPharmacology
2008English

Age-Related Macular Degeneration

2013English

Age Related Macular Degeneration

BMJ
2010English

Combination of Bevacizumab and Photodynamic Therapy vs. Bevacizumab Monotherapy for the Treatment of Wet Age‑related Macular Degeneration: A Meta‑analysis of Randomized Controlled Trials

Experimental and Therapeutic Medicine
MedicineCancer ResearchImmunologyMicrobiology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy